Loading people...
Alexander Vos is a Venture Partner at BioGeneration Ventures, Chairman of Scenic Biotech, and an Independent Director at Alpha Teknova, based in the Amsterdam area of the Netherlands. He previously served as the Chief Executive Officer for multiple biopharmaceutical companies, including VarmX, where he secured a €30 million Series B2 financing round, and VectorY, where he raised an additional €30 million. Furthermore, Vos led contract manufacturing organization PharmaCell to a successful acquisition by Lonza in 2017, following earlier executive roles at Genzyme Therapeutics Europe and the pharmaceutical practice at McKinsey & Company. He holds a master's degree in pharmacy and pharmacology from the University of Amsterdam and an MBA from Stanford University. His current focus centers on guiding early-stage European biotechnology companies specializing in cell and gene therapies, orphan drugs, and rare diseases.
Alexander Vos is a distinguished Venture Partner at BGV (BioGeneration Ventures), a prominent European venture capital firm renowned for its commitment to fostering innovation in the early-stage life sciences sector. At BGV, Alexander Vos plays a crucial role in shaping the future of biotechnology by identifying, evaluating, and investing in companies poised to make a significant impact on human health. His expertise is particularly vital in navigating the complex landscape of early-stage drug discovery and development.
BGV (BioGeneration Ventures) is dedicated to building and growing successful biotech companies in Europe, focusing on novel therapeutics and cutting-edge platform technologies. As a Venture Partner, Alexander Vos contributes significantly to this mission. He works closely with BGV's investment team and portfolio companies, providing strategic guidance, operational insights, and mentorship to help these ventures overcome challenges and accelerate their growth. His involvement spans from initial due diligence to active board participation, ensuring that promising scientific breakthroughs translate into viable commercial products.
Alexander Vos brings a wealth of experience from a distinguished career within the pharmaceutical and biotech industries. Prior to his role at BGV, he held various leadership positions where he was instrumental in strategic development, commercialization, and operational management of innovative therapies. This extensive background provides him with a deep understanding of the entire drug development lifecycle, from preclinical research to market entry. His operational acumen and strategic vision are invaluable assets to the early-stage companies BGV supports, helping them to refine their business models and navigate regulatory pathways.
His investment focus at BGV (BioGeneration Ventures) centers on companies developing novel therapeutics that address significant unmet medical needs. This includes a broad spectrum of areas within biotechnology, such as oncology, immunology, rare diseases, and gene therapies, as well as disruptive platform technologies that can enable new approaches to treatment. While specific notable investments are part of BGV's confidential portfolio strategy, Alexander Vos is actively involved in identifying the next generation of biotech leaders and contributing to the success of BGV's diverse and impactful portfolio. His dedication to fostering scientific excellence and commercial viability underscores his commitment to advancing life sciences innovation.
Through his strategic contributions, Alexander Vos helps BGV (BioGeneration Ventures) continue its legacy of backing companies that not only deliver strong financial returns but also bring transformative medicines to patients worldwide. His leadership and deep industry knowledge are key drivers in BGV's mission to build a healthier future.
Alexander Vos is a Venture Partner at BGV (BioGeneration Ventures), a leading European venture capital firm specializing in early-stage life sciences. He leverages his extensive industry experience to identify, evaluate, and support groundbreaking biotech companies.
Alexander Vos, through BGV (BioGeneration Ventures), invests in early-stage biotech companies focused on novel therapeutics and cutting-edge platform technologies. His investment focus includes areas like oncology, immunology, rare diseases, and gene therapies, addressing significant unmet medical needs.
Alexander Vos works as a Venture Partner at BGV (BioGeneration Ventures), a prominent European venture capital firm dedicated to investing in and building successful early-stage life science companies.
